Valuation: ORIC Pharmaceuticals, Inc.

Market Cap 1.2B 1.08B 1.01B 914M 1.72B 114B 1.73B 12.1B 4.72B 59.33B 4.51B 4.41B 191B P/E 2026 *
-7.64x
P/E 2027 * -6.85x
Enterprise Value 1.2B 1.08B 1.01B 914M 1.72B 114B 1.73B 12.1B 4.72B 59.33B 4.51B 4.41B 191B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
98.41%
Yield 2026 *
-
Yield 2027 * -
1 week-3.00%
Current month-13.50%
1 month-4.39%
3 months+12.40%
6 months+16.29%
Current year+50.00%
1 week 9.76
Extreme 9.76
10.89
1 month 9.76
Extreme 9.76
12.32
3 years 3.7
Extreme 3.7
14.9
5 years 2.2
Extreme 2.2
15.4
Manager TitleAgeSince
Chief Executive Officer 47 06/05/2018
Director of Finance/CFO 52 31/08/2019
Chief Tech/Sci/R&D Officer - 17/08/2025
Director TitleAgeSince
Chairman 68 06/03/2018
Director/Board Member 47 06/05/2018
Director/Board Member 62 31/01/2020
Change 5-day change 1-year change 3-year change Capi.($)
+2.78%-4.46%-9.21%+99.04% 1.17B
-2.01%-7.86%+60.74%+70.97% 70.44B
+3.84%-11.02%+8.59%+57.43% 50.31B
+3.35%+1.42%+11.85%+40.01% 47.51B
+0.51%+1.51%+27.96%+31.43% 42.91B
+2.70%-3.66%+307.41%+547.01% 40.39B
+0.69%-3.44%+9.52%+96.59% 39.69B
+0.06%-2.02%+11.25%+43.27% 30.59B
+0.12%-8.17%+38.23%+1.39% 26.8B
-0.39%-6.92%-13.60%-14.40% 22.36B
Average +0.96%-5.11%+45.27%+97.27% 41.22B
Weighted average by Cap. +0.97%-4.90%+54.60%+102.69%

Financials

2026 *2027 *
Net sales - -
Net income -166M -149M -139M -126M -237M -15.8B -239M -1.67B -653M -8.2B -623M -610M -26.38B -199M -179M -167M -151M -284M -18.96B -286M -2.01B -783M -9.84B -748M -732M -31.65B
Net Debt - -
Projected Income Statement - Annual - ORIC Pharmaceuticals, Inc.
Logo ORIC Pharmaceuticals, Inc.
ORIC Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on improving patients’ lives by Overcoming Resistance In Cancer. The Company is advancing a diverse pipeline of clinical and discovery stage therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology and key tumor dependencies. The Company's clinical-stage product candidates include ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 (PRC2) via the EED subunit, being developed for prostate cancer, and ORIC-114, a brain penetrant inhibitor that selectively targets EGFR exon 20, HER2 exon 20 and EGFR atypical mutations, being developed across multiple genetically defined cancers. In addition, the Company is also developing multiple discovery stage precision medicines targeting other hallmark cancer resistance mechanisms. Its out-licensing candidates include ORIC-533 and ORIC-613.
Employees
-
Date Price Change
14/10/26 €10.35 +2.78%
13/10/26 €10.07 -4.50%
12/10/26 €10.55 -1.13%
09/10/26 €10.67 -0.19%
08/10/26 €10.69 +0.14%
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
MarketScreener Ratings - ORIC Pharmaceuticals, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
16
Last Close Price
11.59USD
Average target price
21.64USD
Spread / Average Target
+86.74%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - ORIC Pharmaceuticals, Inc.